Aligos Therapeutics, Inc. Common Stock (NASDAQ: ALGS) last traded at $5.12, down 3.76% on the session. The quote above updates while this page is open; the figures below are drawn from Aligos Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Aligos Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker ALGS. Its market capitalisation is $31.93 million.
Valuation measures for Aligos Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $31.93M |
|---|---|
| Enterprise value | $35.99M |
| Price / sales | 8.54 |
| Price / book | 1.00 |
| Beta | 1.40 |
Trailing-twelve-month figures tagged in Aligos Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $3.74M |
|---|---|
| Net income (TTM) | -$75.96M |
| Operating margin | -2112.14% |
| Return on equity | -238.24% |
| Cash | $30.38M |
Range and volume for ALGS over the past 52 weeks.
| 52-week high | $13.69 |
|---|---|
| 52-week low | $3.98 |
| Volume | 9.4K |
| Average volume | 95.0K |
| Previous close | $5.32 |
Invest a chosen dollar amount in Aligos Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell ALGS.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.